Economic evaluation of donepezil in moderate to severe Alzheimer disease

Neurology. 2005 Apr 12;64(7):1320; author reply 1320. doi: 10.1212/wnl.64.7.1320.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Cost-Benefit Analysis
  • Donepezil
  • Humans
  • Indans / economics*
  • Indans / therapeutic use*
  • Neuropharmacology / economics*
  • Neuropharmacology / standards*
  • Nootropic Agents / economics
  • Nootropic Agents / therapeutic use
  • Piperidines / economics*
  • Piperidines / therapeutic use*
  • Placebos / economics
  • Placebos / therapeutic use
  • Reproducibility of Results

Substances

  • Indans
  • Nootropic Agents
  • Piperidines
  • Placebos
  • Donepezil